sFLT1, PlGF, the sFLT1/PlGF Ratio and Their Association with Pre-Eclampsia in Twin Pregnancies-A Review of the Literature.
PlGF
adverse outcomes
sFLT1
sFLT1/PlGF ratio
twin pregnancy
twins
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
31
03
2023
revised:
24
05
2023
accepted:
07
06
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Twin pregnancies demonstrate a 2-3-fold higher chance of developing PE compared to singletons, and recent evidence has demonstrated that the sFLT1/PIGF ratio is strongly associated with PE, adverse pregnancy outcomes, as well as imminent deliveries due to PE complications. The primary objective of this systematic review was to summarise the available data on the levels of sFLT1, PlGF and their ratios in twin pregnancies and to investigate their association with the development of PE, adverse pregnancy outcomes and the timing of the delivery. A systematic search of Ovid Embase, Web of Science, Science Direct, PubMed, Ovid Medline, Google Scholar and CINAHL was carried out. sFLT1 levels and the sFLT1/PIGF ratio appeared higher in twins compared to singleton pregnancies, especially in the third trimester, while PlGF levels appeared higher up until the third trimester, with their values showing no difference or being even lower than in singletons thereafter. The sFLT1/PIGF ratio has been reported to be an independent marker of adverse outcomes related to pre-eclampsia and is associated with the mean time until delivery in an inverse manner. Further research is required in order to establish the optimal sFLT1/PIGF cut-off values and to stratify the risk of adverse outcomes in twin pregnancies.
Identifiants
pubmed: 37512044
pii: medicina59071232
doi: 10.3390/medicina59071232
pmc: PMC10386152
pii:
doi:
Substances chimiques
Biomarkers
0
FLT1 protein, human
EC 2.7.10.1
Placenta Growth Factor
144589-93-5
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
PGF protein, human
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Fetal Diagn Ther. 2018;44(2):142-148
pubmed: 28898871
Am J Obstet Gynecol. 2010 Feb;202(2):161.e1-161.e11
pubmed: 19850276
Ultrasound Obstet Gynecol. 2017 Sep;50(3):373-382
pubmed: 27883242
BJOG. 2019 May;126(6):755-762
pubmed: 30548506
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Hypertension. 2020 Jul;76(1):176-183
pubmed: 32450740
Diagnostics (Basel). 2021 Jun 29;11(7):
pubmed: 34209832
Hypertension. 2020 Mar;75(3):755-761
pubmed: 31983309
Hum Reprod. 2012 Feb;27(2):358-65
pubmed: 22116949
Ultrasound Obstet Gynecol. 2015 Mar;45(3):286-93
pubmed: 25491901
Twin Res. 2002 Feb;5(1):8-14
pubmed: 11893276
Hypertension. 2020 Apr;75(4):918-926
pubmed: 32063058
PLoS One. 2010 Oct 11;5(10):e13263
pubmed: 20948996
Fetal Diagn Ther. 2021;48(4):288-296
pubmed: 33784677
Am J Perinatol. 2013 Aug;30(7):607-12
pubmed: 23208763
Pregnancy Hypertens. 2021 Jun;24:37-43
pubmed: 33647841
Int J Reprod Biomed. 2016 May;14(5):317-22
pubmed: 27326416
Am J Obstet Gynecol. 2008 Feb;198(2):200.e1-7
pubmed: 18226624
Lancet Glob Health. 2014 Jun;2(6):e323-33
pubmed: 25103301
Hypertension. 2012 Aug;60(2):451-8
pubmed: 22753210
Hypertens Pregnancy. 2021 Nov;40(4):330-335
pubmed: 34697976
Hypertension. 2014 Feb;63(2):346-52
pubmed: 24166751
BMC Pregnancy Childbirth. 2014 Sep 18;14:324
pubmed: 25230734
Am J Obstet Gynecol. 2015 May;212(5):636.e1-8
pubmed: 25434840
Fetal Diagn Ther. 2018;43(2):81-89
pubmed: 28719896
Pregnancy Hypertens. 2018 Oct;14:222-227
pubmed: 29678353
Fetal Diagn Ther. 2022;49(4):206-214
pubmed: 35609518
Am J Obstet Gynecol. 2008 Apr;198(4):428.e1-6
pubmed: 18191808
Obstet Gynecol. 2003 Oct;102(4):806-15
pubmed: 14551012
Am J Obstet Gynecol. 2012 Jan;206(1):58.e1-8
pubmed: 22000672
Am J Obstet Gynecol. 2012 Nov;207(5):407.e1-7
pubmed: 22981320
J Am Coll Cardiol. 2019 Apr 30;73(16):2106-2116
pubmed: 31023435